{"id":3932,"date":"2026-10-27T09:00:00","date_gmt":"2026-10-27T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3932"},"modified":"2026-10-27T20:53:09","modified_gmt":"2026-10-28T00:53:09","slug":"albendazole-study-probes-b-all-ferroptosis","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3932","title":{"rendered":"Albendazole Study Probes B ALL Ferroptosis"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Guangzhou investigators (academic, China)<\/p>\n

Event Type<\/strong><\/p>\n

Peer-reviewed publication<\/p>\n

Modality<\/strong><\/p>\n

Repurposed small molecule; CAR-T combination<\/p>\n

Asset<\/strong><\/p>\n

Albendazole<\/p>\n

Target<\/strong><\/p>\n

USP7\u2013GPX4 axis; PD-L1<\/p>\n

Disease Area<\/strong><\/p>\n

B-cell acute lymphoblastic leukemia<\/p>\n

Summary<\/h4>\n

A peer-reviewed Communications Biology paper posted online 27 October reports that albendazole promotes B-ALL ferroptosis through a USP7\u2013GPX4 axis and improves CD19 CAR-T activity in experimental models. This is a drug-repurposing hypothesis, not clinical evidence for albendazole in leukemia.<\/p>\n

The China-based investigators report that USP7 deubiquitinates and stabilizes the ferroptosis suppressor GPX4. Albendazole destabilized USP7, reduced GPX4, increased lipid-peroxidation-mediated killing, and lowered leukemia-cell PD-L1 in experimental systems. The accompanying deposited research description reports increased CD19 CAR-T activity in vitro and in vivo. The journal\u2019s online date is 27 October; earlier repository deposits and preprint-like material should not be mistaken for this peer-reviewed publication date.<\/p>\n

Deep Analysis<\/h4>\n

The study links a tractable drug to a mechanistic leukemia vulnerability and a potential immune combination. However, approved antiparasitic dosing cannot be assumed to yield effective marrow concentrations, and the exposure needed for USP7\/GPX4 modulation must be compared with human PK and tolerability. GPX4 protects normal tissues as well as cancer cells, so systemic ferroptosis liability and on-target marrow effects need study. Differences between cell lines, xenografts and heterogeneous patient blasts, and possible off-target effects of albendazole, temper target attribution. The CAR-T combination requires sequencing, cytokine and persistence data. Formulation, IP around repurposing, and competitive alternatives affect translation.<\/p>\n

Company and Product Background<\/h4>\n

B-cell acute lymphoblastic leukemia can relapse after chemotherapy and CD19-targeted therapy. Ferroptosis is iron-dependent lipid-peroxidation cell death restrained by GPX4; albendazole is an antiparasitic benzimidazole.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> USP7\u2013GPX4 is a B-ALL dependency that can be pharmacologically exploited; perturbation and model responses support it.<\/li>\n
  • Interpretation B:<\/strong> high-concentration, pleiotropic albendazole effects dominate and are not clinically reachable; absent human exposure and therapeutic index data support caution.<\/li>\n
  • Upgrade<\/strong> with primary-patient xenografts, genetic rescue, human-relevant PK and normal-marrow safety. Downgrade<\/strong> with efficacy only above tolerated exposure. Falsification:<\/strong> selective USP7 or GPX4 perturbation fails to reproduce the phenotype in independent models.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: the peer-reviewed work identifies a plausible preclinical combination thesis; clinical repurposing remains unvalidated.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 3 of 5. Signal Direction: positive preclinical mechanism; clinical uncertain. Confidence in Facts: moderate. Confidence in Interpretation: low to moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A peer-reviewed Communications Biology paper posted online 27 October reports that albendazole promotes B-ALL ferroptosis through a USP7\u2013GPX4 axis and improves CD19 CAR-T activity in experimental models. This is a drug-repurposing hypothesis, not clinical…<\/p>\n","protected":false},"author":1,"featured_media":3944,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1242,1244,1189,1243,1246,1245],"class_list":["post-3932","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-albendazole","tag-b-all","tag-car-t-2","tag-ferroptosis","tag-gpx4","tag-usp7"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3932"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3932\/revisions"}],"predecessor-version":[{"id":3952,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3932\/revisions\/3952"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3944"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}